Q-omics provides the consensus-scored MIR217HG profile across patient tissues and cancer cell-line models. MIR217HG expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR217HG is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, MIR217HG RNA expression shows 11,421 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCEC, KIRC, and PDAC as cancer lineages where MIR217HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR217HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR217HG survival associations across molecular data types. MIR217HG RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR217HG RNA expression–survival associations across cancer types. High MIR217HG expression shows unfavorable associations in UCEC, STAD, LGG, COAD, ACC and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR217HG RNA expression.
This table summarizes MIR217HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR217HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR217HG shows lower tumor expression in KIRC, KIRP, KICH and LUSC and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher MIR217HG RNA expression in normal versus tumor tissue (log2 FC = −0.134, t-test p < 0.001).
This table shows molecular features associated with MIR217HG in patient tissues and cancer cell lines. In patient samples, MIR217HG shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
